Sirt3在原发性肝细胞癌中的表达及其抑瘤作用
The expression and inhibition effect of Sirt3 on primary hepatocellular carcinoma
作者：吴思思;丁雨;陈雪梅;蒋维;
Author：
收稿日期： 年卷（期）页码：2016,31(05):-477-479
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：Sirt3;腺病毒载体;过表达;HepG2细胞;原发性肝癌;抑瘤作用;治疗靶点
Key words：
基金项目：国家自然科学基金资助项目(批准号:81000056)
中文摘要
目的观察Sirt3在原发性肝细胞癌(HCC)中的表达,并探讨过表达h Sirt3对人肝癌Hep G2细胞的存活及增殖影响。方法采用免疫组化法检测HCC组织和癌旁正常肝组织中Sirt3的表达;构建h Sirt3腺病毒载体,转染Hep G2细胞并过表达Sirt3蛋白,采用WST-1和Edu实验评价Sirt3对Hep G2细胞的存活及增殖作用。结果与正常肝组织比较,肝癌组织的Sirt3表达量明显降低;Ad-h Sirt3腺病毒感染Hep G2细胞后明显降低了细胞的存活率,抑制细胞生长。结论肝癌组织中Sirt3呈低表达或表达缺失,提示Sirt3的下调可能与HCC的发生密切相关;过表达Sirt3明显抑制Hep G2细胞株的存活及增殖,提示Sirt3可能是治疗肝癌的潜在靶点。
参考文献
[1]Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].Cancer J Clin,2011,61(2):69-90.
[2]Zhang YY,Zhou LM.Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation[J].Biochem Biophys Res Commun,2012,423(1):26-31.
[3]Labarre DD,Lowy RJ.Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays[J].J Virol Methods,2001,96(2):107-126.
[4]Chen Y,Fu L,Wen X,et al.Sirtuin-3(Sirt3),a therapeutic target with oncogenic and tumor-suppressive function in cancer[J].Cell Death Dis,2014,5:e1047.
[5]Jacobs KM,Pennington JD,Bisht KS,et al.Sirt3 interacts with the daf-16 homolog FOXO3a in the mitochondria,as well as increases FOXO3a dependent gene expression[J].Int J Bio Sci,2008,4(5):291-299.
[6]Reilly CM,Thomas M,Gogal R,et al.The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice[J].J Autoimmun,2008,31(2):123-130.
【关闭】
